Abstract Rationale: In this paper, we report on 2 patients who developed branch retinal vein occlusion (BRVO) exacerbation 1 day after administration of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine. Patient concerns: Case 1: A 71 year-old female developed vision loss in her left eye 1 day after receiving a second dose of the SARS-CoV-2 mRNA vaccine. This patient was diagnosed with temporal inferior BRVO and secondary macular edema (ME) in her left eye. ME resolved after 3 doses of intravitreal aflibercept (IVA). After treatment, no recurrence of ME was observed. Case 2: A 72 year-old man developed vision loss in his right eye 1 day after receiving the first dose of the SARS-CoV-2 mRNA vaccine. This patient was diagnosed with temporal superior BRVO in the right eye without ME. The patient was followed up and did not undergo any additional treatment. Diagnoses: Case1: Temporal superior BRVO and secondary ME were observed in the left eye. Her best-corrected visual acuity (BCVA) was 20/30. Case2: Temporal superior BRVO recurrence and secondary ME were observed in the right eye. BCVA was 20/25. Interventions: Case1: Additional dose of IVA was administered. Case2: Two times of Intravitreal ranibizumab was administered twice. Outcomes: Case1: Subsequently, ME resolved BCVA was 20/20. Case2: Subsequently, ME resolved BCVA was 20/25. Lessons: Both cases showed a possible association between SARS-CoV-2 vaccination and the exacerbation of BRVO.
【저자키워드】 COVID-19, vaccination, Case report, Adverse reaction, branch retinal vein occlusion, 【초록키워드】 Treatment, mRNA vaccine, SARS-CoV-2 vaccine, BNT162b2, female, Patient, edema, recurrence, Pfizer-BioNTech, SARS-CoV-2 vaccination, association, administration, dose, left eye, retinal vein occlusion, macular edema, Exacerbation, second dose, first dose, diagnoses, visual acuity, Administered, Right eye, aflibercept, ranibizumab, retinal vein, diagnosed, receiving, undergo, Temporal, resolved, intravitreal, the SARS-CoV-2, 【제목키워드】 SARS-CoV2,